Evidence map›Paper›PMID 42201242›Full record

ArticleJournal of developmental biology2026

Adenosine Receptor Functionality and Desensitization Machinery in a Neuronal Cell Model of Angelman Syndrome.

Martina Contestabile, Jacqueline Fátima Martins de Almeida, Chiara De Cesari, Ilaria Tonazzini, Paolo Giovanni Artini, Simona Daniele

Abstract read
In one paragraph

Article in Journal of developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Martina ContestabileDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0009-0000-1146-4626
Jacqueline Fátima Martins de AlmeidaDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.
Chiara De CesariIstituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR), @NEST-SNS, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0009-0004-2305-966X
Ilaria TonazziniIstituto Nanoscienze, Consiglio Nazionale delle Ricerche (CNR), @NEST-SNS, Piazza San Silvestro 12, 56127 Pisa, Italy.ORCID 0000-0002-7323-2174
Paolo Giovanni ArtiniDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-7164-0553
Simona DanieleDepartment of Pharmacy, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0001-7391-3087

Funding

Angelman Syndrome Alliance (ASA) Angelman Syndrome Alliance (ASA) research grant 2021 - project InnovAS.Ministero dell'Istruzione e del Merito PRIN2022 2022ZH5M72 - project ENGInerve
6 · The paper itself

Abstract

Angelman syndrome (AS) is a neurodevelopmental disorder caused by the loss of maternal UBE3A expression, leading to disrupted proteostasis and synaptic dysfunction. Adenosine is a ubiquitous neuromodulator whose G protein-coupled receptors (ARs) regulate neuronal differentiation and neurite outgrowth during development. Here, we investigated AR signaling and their influence on survival-autophagy balance and neuronal morphology in an AS cellular model. Using SH-SY5Y cells with silenced UBE3A, we found that UBE3A loss markedly decreased A1AR, A2BAR, and A3AR protein levels while significantly increasing A2AR expression. Ligand affinity was preserved across genotypes, but A1AR and A2AAR desensitization kinetics were significantly slower in UBE3A-deficient cells. These effects were associated with reduced recruitment of G protein-coupled receptor kinase 2 (GRK2) to the plasma membrane and decreased GRK2-AR association in UBE3A-deficient cells, suggesting a possible contribution of altered GRK2 dynamics to prolonged AR signaling. Functionally, A1AR and A2AR agonists preferentially promoted survival of UBE3A-deficient cells and modulated the MDM2-p53 axis and autophagy markers; A1R stimulation also increased neurite density in UBE3A-deficient cells. Together, these results identify AR-level alterations and defective desensitization machinery in AS neuronal cells and link receptor changes to downstream proteostasis and morphological phenotypes relevant to AS pathophysiology.

Indexed as

adenosine receptorsangelman syndromereceptor desensitizationsignaling pathways

Identifiers

PMID42201242
PMCPMC13214759

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.